IMM Immupharma Plc

RNS Number:9139T
Immupharma PLC
08 May 2008


For immediate release                                                 8 May 2008

                                 ImmuPharma plc
                        PRELIMINARY RESULTS ANNOUNCEMENT
                       for the year ended 31 December 2007


ImmuPharma plc (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist
pharmaceutical discovery and development company is pleased to announce its
preliminary results for the year ended 31 December 2007.


Key Highlights:
     
*    Recruitment of patients well underway with IPP-201101, drug candidate for 
     the treatment of Systemic Lupus Erythematosus, in pivotal Phase IIb trial

*    Added a novel drug candidate to the pipeline, IPP-204106, for cancer;
     rights obtained from Centre National de la Recherche Scientifique (CNRS)

*    Discovery of a new lead candidate for inflammation, IPP-201007 from
     internal proprietary chemical library

*    Consolidated cash balance at 31 December 2007 of approx #2.9 million

Dimitri Dimitriou, Chief Executive Officer, said:  "2007 was an exciting year
for ImmuPharma with good progress being made through our pipeline, particularly
for our lead drug candidate IPP-201101 for Lupus and the addition of two new
compounds to our portfolio.  We look forward to reporting on further progress
throughout 2008 principally the results of our Phase IIb trial for Lupus."


For further information please contact:

 ImmuPharma plc
 Dimitri Dimitriou, Chief Executive Officer                     +44 20 7152 4080
 Richard Warr, Chairman                                         +44 20 7152 4080
 Dr Robert Zimmer, Chief Scientific Officer                     +33 389 32 76 50

 Buchanan Communications                                        +44 20 7466 5000
 Lisa Baderoon, Rebecca Skye-Dietrich

 Panmure Gordon & Co                                            +44 151 243 0963
 Andrew Burnett


 IMMUPHARMA PLC

The consolidated results for ImmuPharma and its subsidiaries (collectively the "
Group") cover the year ended 31 December 2007.


REPORT FROM THE CHAIRMAN AND THE CHIEF EXECUTIVE OFFICER

We are pleased to report our achievements and continued progress during 2007 and
are enthusiastic about our plans for 2008.  2007 has been an important year in
our corporate history.  During our second year as a public company we have made
a number of key achievements including the addition of two novel drug candidates
to our portfolio and the continued progress of our most advanced asset in
development, our lead candidate for the treatment of Lupus.

Following the successful completion of a phase II study in patients suffering
from Lupus, where our lead drug candidate (IPP-201101) showed a statistically
significant clinical improvement in patients' overall symptoms, ImmuPharma has
initiated a Phase IIb, double-blind, placebo-controlled trial in 200 patients in
Europe and Latin America.  The first patients have been dosed and the Company
expects to report headline efficacy data in summer of 2008.  Analysts estimate
that IPP-201101 for the treatment of Lupus has blockbuster sales potential.

ImmuPharma was delighted to announce the addition of two novel drug candidates
to our portfolio during 2007.  IPP-204106 is a novel drug candidate for cancer,
the rights to which have been obtained through the Company's ongoing research
collaboration with the Centre National de la Recherche Scientifique (CNRS),
France's leading scientific research institution.  The molecule is a nucleolin
antagonist and has a dual mechanism of action, acting both in preventing
angiogenesis as well as proliferation.  Preclinical data has shown that
nucleolin antagonists inhibit the growth of tumours and metastasis in many
cancer types.

Following investigation of our proprietary chemical library, ImmuPharma has
discovered a new molecular series with potential application in inflammatory/
allergic conditions such as asthma and rheumatoid arthritis.  These molecules,
programme code-named IPP-201007, have utility as selective phospholipase A2
subtype inhibitors and are already patented through ImmuPharma's library broad
patent.

Summary and Outlook

The ImmuPharma business model is to focus on innovative drugs for niche
therapeutic areas with significant sales potential but without the need for a
large commercial infrastructure.  In contrast to other types of pharmaceutical
development, this is characterised by relatively streamlined development costs
and timelines.  This is evident in our progress so far with IPP-201101 for the
treatment of Lupus.

ImmuPharma is in discussions with a number of pharmaceutical companies regarding
potential licensing deals.  The Company intends to optimise the value of its
asset portfolio and to maximise the return to its shareholders.

The focus for the year ahead will be on the current and next phase of trials for
our Lupus compound, IPP-201101; to make progress advancing our other compounds,
particularly our new cancer compound, IPP-204106, and to continue in dialogue
with other pharmaceutical companies in respect of potential corporate deals.

With a strong team in place to execute these objectives, we believe we are well
positioned to take the Group forward.

The Board of ImmuPharma should like to thank its shareholders for their support
as well as its scientific advisors and the Centre Nationale de la Recherche
Scientifique in France for their collaboration.


REPORT FROM THE CHIEF SCIENTIFIC OFFICER

2007 has been a year of exciting progress and new developments for ImmuPharma.
Following the successful Phase II trial in 2006 and further to discussions with
the US Food and Drug Administration (FDA), the first patients have been dosed
with IPP-201101, our lead candidate for the treatment of Lupus, in a pivotal
Phase IIb trial.  Two new drug candidates have been discovered.  The first one
announced chronologically, IPP-201007, was discovered from our proprietary
chemical library and has potential application in inflammatory/allergic
conditions.  The second, IPP-204106, represents an exciting approach to
potentially treating cancer and is a further validation of the value of our
ongoing collaboration with the Centre National de la Recherche Scientifique
(CNRS), France's leading scientific research institution.  Furthermore, general
progress on our other pipeline assets continues to be made.

IPP-201101 Lupus Drug Candidate

Following a Phase I study showing IPP-201101 to be generally safe and
well-tolerated and the successful completion of a Phase II study in Lupus
patients which met all of its primary endpoints (p

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024